Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes.

Balemans W, Van Hul W.

Endocrinology. 2007 Jun;148(6):2622-9. Epub 2007 Mar 29. Review.

PMID:
17395706
2.

LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.

Levasseur R, Lacombe D, de Vernejoul MC.

Joint Bone Spine. 2005 May;72(3):207-14. Review.

PMID:
15850991
3.

The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.

Sawakami K, Robling AG, Ai M, Pitner ND, Liu D, Warden SJ, Li J, Maye P, Rowe DW, Duncan RL, Warman ML, Turner CH.

J Biol Chem. 2006 Aug 18;281(33):23698-711. Epub 2006 Jun 20.

4.

Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity.

Korvala J, Jüppner H, Mäkitie O, Sochett E, Schnabel D, Mora S, Bartels CF, Warman ML, Deraska D, Cole WG, Hartikka H, Ala-Kokko L, Männikkö M.

BMC Med Genet. 2012 Apr 10;13:26. doi: 10.1186/1471-2350-13-26.

5.

Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites.

Ferrari SL, Deutsch S, Choudhury U, Chevalley T, Bonjour JP, Dermitzakis ET, Rizzoli R, Antonarakis SE.

Am J Hum Genet. 2004 May;74(5):866-75. Epub 2004 Apr 7.

6.

[Wnt signaling molecules related to osteoporosis].

Kubota T, Ozono K.

Clin Calcium. 2013 Jun;23(6):855-60. doi: CliCa1306855860. Review. Japanese.

PMID:
23719498
7.

[Cytokines in bone diseases. Wnt signaling and osteoporosis-pseudoglioma syndrome].

Ozono K.

Clin Calcium. 2010 Oct;20(10):1520-5. doi: CliCa101015201525. Review. Japanese.

PMID:
20890034
8.

Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling.

Balemans W, Devogelaer JP, Cleiren E, Piters E, Caussin E, Van Hul W.

J Bone Miner Res. 2007 May;22(5):708-16.

9.

Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.

Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R.

J Bone Miner Res. 2006 Nov;21(11):1738-49.

10.

[Regulation of bone metabolism by pathogenic mutations and polymorphism in the LRP5-Wnt signaling genes].

Urano T.

Nihon Rinsho. 2007 Nov 28;65 Suppl 9:95-100. Review. Japanese. No abstract available.

PMID:
18161089
12.

[Wnt-beta-catenin signaling in bone metabolism].

Urano T.

Clin Calcium. 2006 Jan;16(1):54-60. Review. Japanese.

PMID:
16397351
13.

Lrp5 functions in bone to regulate bone mass.

Cui Y, Niziolek PJ, MacDonald BT, Zylstra CR, Alenina N, Robinson DR, Zhong Z, Matthes S, Jacobsen CM, Conlon RA, Brommage R, Liu Q, Mseeh F, Powell DR, Yang QM, Zambrowicz B, Gerrits H, Gossen JA, He X, Bader M, Williams BO, Warman ML, Robling AG.

Nat Med. 2011 Jun;17(6):684-91. doi: 10.1038/nm.2388. Epub 2011 May 22.

14.

Clinical and molecular findings in osteoporosis-pseudoglioma syndrome.

Ai M, Heeger S, Bartels CF, Schelling DK; Osteoporosis-Pseudoglioma Collaborative Group.

Am J Hum Genet. 2005 Nov;77(5):741-53. Epub 2005 Sep 27.

15.

LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.

Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Jüppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML; Osteoporosis-Pseudoglioma Syndrome Collaborative Group.

Cell. 2001 Nov 16;107(4):513-23.

16.

The role of the Wnt signaling pathway in osteoblast commitment and differentiation.

Yavropoulou MP, Yovos JG.

Hormones (Athens). 2007 Oct-Dec;6(4):279-94. Review.

17.

Low density lipoprotein receptor-related protein 5 (LRP5) mutations and osteoporosis, impaired glucose metabolism and hypercholesterolaemia.

Saarinen A, Saukkonen T, Kivelä T, Lahtinen U, Laine C, Somer M, Toiviainen-Salo S, Cole WG, Lehesjoki AE, Mäkitie O.

Clin Endocrinol (Oxf). 2010 Apr;72(4):481-8. doi: 10.1111/j.1365-2265.2009.03680.x. Epub 2009 Aug 5.

PMID:
19673927
18.

Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.

Chang MK, Kramer I, Keller H, Gooi JH, Collett C, Jenkins D, Ettenberg SA, Cong F, Halleux C, Kneissel M.

J Bone Miner Res. 2014 Jan;29(1):29-42. doi: 10.1002/jbmr.2059.

19.

N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/beta-catenin signaling, osteoblast function, and bone formation.

Haÿ E, Laplantine E, Geoffroy V, Frain M, Kohler T, Müller R, Marie PJ.

Mol Cell Biol. 2009 Feb;29(4):953-64. doi: 10.1128/MCB.00349-08. Epub 2008 Dec 15.

20.

Supplemental Content

Support Center